Gustavo Monnerat, Deputy Editor at The Lancet, shared a post on LinkedIn:
“Phase 3 Trial Doubled Median Survival in Metastatic Pancreatic Cancer.
Daraxonrasib blocks the active form of RAS, and in metastatic pancreatic cancer it beat chemotherapy on every main endpoint:
- Median overall survival 13.2 vs 6.7 months (HR 0.40)
- Progression-free survival 7.2 vs 3.6 months
Still early evidence. But very exciting findings, and a big effort all the way from basic science to phase 3.”
Title: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Authors: Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin
Read the Full Article.
Other articles featuring Gustavo Monnerat on OncoDaily.